Abstract: The present invention provides a retroviral or lentiviral vector having a viral envelope which comprises a mitogenic T-cell activating transmembrane protein which comprises: (i) a mitogenic domain which binds a mitogenic tetraspanin, and (ii) a transmembrane domain; wherein the mitogenic T-cell activating transmembrane protein is not part of a viral envelope glycoprotein. When cells such as T-cells or Natural Killer cells are transduced by such a viral vector, they are activated by the mitogenic T-cell activating transmembrane protein.

Abstract: The present invention relates to a novel class of compounds and to compositions comprising the same as well as their used as medicaments in the treatment of cancer.

Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.

Abstract: The invention relates to novel linkers which comprise two or three basic, acidic or hydrophobic natural or non-natural amino acids. The invention also relates to drug conjugates comprising said linkers, to pharmaceutical compositions comprising said drug conjugates and to the use of said drug conjugates in preventing, suppressing or treating cancer.

Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.

Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.

Abstract: A steel alloy providing from 0.05 to 0.25 wt. % carbon, from 10 to 14 wt. % chromium, from 1.5 to 4 wt. % molybdenum, from 0.3 to 1.2 wt. % vanadium, from 0.3 to 3 wt. % nickel, from 6 to 11 wt. % cobalt from 0.05 to 0.4 wt. % silicon, from 0.1 to 1 wt. % manganese, from 0.02 to 0.06 wt. % niobium, optionally one or more of the following elements from 0 to 2.5 wt. % copper from 0 to 0.1 wt. % aluminum, from 0 to 250 ppm nitrogen, from 0 to 30 ppm boron, and the balance iron, together with any unavoidable impurities, wherein the alloy has a Nieq of greater than 11.5, the Nieq being defined by the formula Nieq=Ni+Co+(0.5×Mn)+(30×C), in wt. %.

Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.

Abstract: A steel alloy for a bearing, the alloy having a composition having from 0.04 to 0.1 wt. % carbon, from 10.5 to 13 wt. % chromium, from 1.5 to 3.75 wt. % molybdenum, from 0.3 to 1.2 wt. % vanadium, from 0.3 to 2.0 wt .% nickel, from 6 to 9 wt. % cobalt, from 0.05 to 0.4 wt. % silicon, from 0.2 to 0.8 wt. % manganese, from 0.02 to 0.06 wt. % niobium, from 0 to 2.5 wt. % copper, from 0 to 0.1 wt. % aluminium, from 0 to 250 ppm nitrogen, from 0 to 30 ppm boron, and the balance iron, together with any unavoidable impurities.

Abstract: A bearing steel composition contains 0.1 to 0.2 wt % C, 3.25 to 4.25 wt % Cr, 9.5 to 11.5 wt % Mo, 5.75 to 6.75 wt % W, 1.5 to 2.5 wt % V, and 2.5 to 3.5 wt % Ni. A bearing component, such as a rolling element, an inner race or outer race, is formed from the bearing steel composition, for example, by a powder metallurgical technique and then is subjected to a case hardening treatment. The bearing component may have a microstructure composed of martensite, retained austenite and at least one of carbides and/or carbonitrides. The carbon level at the surface of the bearing component may be 0.5 to 1.1 wt %.

Abstract: A bearing component formed from a steel composition and providing carbon, silicon, manganese, chromium, cobalt, vanadium, and at least one of the following elements sulphur, phosphorous, molybdenum, aluminum, arsenic, tin, antimony, and the balance iron, together with impurities.

Abstract: A steel alloy for a bearing is provided. The alloy having a composition including from 0.04 to 0.1 wt. % carbon, from 11.5 to 13 wt. % chromium, from 1.5 to 3.5 wt. % molybdenum, from 0.3 to 0.8 wt. % vanadium, from 0.3 to 1.75 wt. % nickel from 6 to 9 wt. % cobalt, from 0.1 to 0.4 wt. % silicon, from 0.2 to 0.8 wt. % manganese, from 0 to 2 wt. % copper, from 0 to 0.05 wt. % niobium, from 0 to 0.1 wt. % aluminum, from 0 to 250 ppm nitrogen, from 0 to 30 ppm boron, and the balance iron, together with any unavoidable impurities.

Abstract: A transducer 1b comprising a vibrator body 2b for generating and/or receiving acoustic or ultrasonic waves, acoustically coupled to a second part 4 for generating and/or receiving acoustic or ultrasonic waves and, a matching layer 5 coupled to said vibrator body 2 so as, in use, to acoustically match the vibrator body 2b to a medium 6 contacting said matching layer 5.

Abstract: A bearing component formed of a steel comprising: (A) from 0.8 to 2.5 wt. % C, (B) from 3.5 to 4.5 wt. % Cr, (C) from 3.9 to 11.25 wt. % Mo, (D) optionally one or more of the following elements: (D1) from 0 to 8.2 wt. % W, (D2) from 0 to 11 wt. % Co, (D3) from 0 to 0.5 wt. % Ni, (D4) from 0 to 6.75 wt. % V, (D5) from 0 to 0.35 wt. % Si, (D6) from 0 to 0.4 wt. % Mn, (D7) from 0 to 0.3 wt. % S, and (D8) from 0 to 0.05 wt. % P, and (E) the balance iron, together with unavoidable impurities.

Abstract: A bearing component formed from a steel composition and providing carbon, silicon, manganese, chromium, cobalt, vanadium, and at least one of the following elements sulphur, phosphorous, molybdenum, aluminium, arsenic, tin, antimony, and the balance iron, together with impurities.

Abstract: The present invention relates to novel piperazine derivatives; to processes for their preparation; to pharmaceutical compositions containing the derivatives; and to the use of the derivatives in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial.

Abstract: The present invention relates to novel piperazine derivatives (I); to processes for their preparation; to pharmaceutical compositions containing the derivatives; and to the use of the derivatives in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial.

Abstract: The invention relates to novel spirocyclic derivatives with affinity for Cav2.2 calcium channels and which are capable of interfering with Cav2.2 calcium channels; to processes for their preparation; to pharmaceutical compositions containing them; and to the use of such compounds in therapy for the treatment of pain.

Abstract: The present invention relates to novel piperazine derivatives; to processes for their preparation; to pharmaceutical compositions containing the derivatives; and to the use of the derivatives in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial.

Abstract: The present invention relates to novel piperazine derivatives; to processes for their preparation; to pharmaceutical compositions containing the derivatives; and to the use of the derivatives in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial.